Longeveron (LGVN) Change in Accured Expenses (2020 - 2026)

Longeveron's (LGVN) quarterly Change in Accured Expenses came in at $293000.0 in Q1 2026, up 270.35% year-on-year from $79114.6 in Q1 2025, and down 76.47% quarter-over-quarter from $1.2 million in Q4 2025.

Longeveron (LGVN) Change in Accured Expenses (2020 - 2026) Analysis & Trends

Longeveron's Change in Accured Expenses history runs 7 years deep, the most recent figure standing at $293000.0 for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses rose 270.35% year-over-year to $293000.0 in Q1 2026; TTM through Mar 2026 was $1.8 million, a 1228.21% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 388.68% from the prior year.
  • Change in Accured Expenses fell to $293000.0 in Q1 2026 per LGVN's latest filing, from $1.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.2 million in Q4 2025 and bottomed at -$604000.0 in Q1 2022.
  • The 5-year median for Change in Accured Expenses is $66000.0 (2024), against an average of $157529.4.
  • Biggest YoY gain for Change in Accured Expenses was 1786.36% in 2025; the steepest drop was 375.76% in 2025.
  • Year by year, Change in Accured Expenses stood at -$78000.0 in 2022, then jumped by 970.51% to $679000.0 in 2023, then slumped by 90.28% to $66000.0 in 2024, then jumped by 1786.36% to $1.2 million in 2025, then slumped by 76.47% to $293000.0 in 2026.
  • Per Business Quant, the three latest LGVN Change in Accured Expenses figures stand at $293000.0 (Q1 2026), $1.2 million (Q4 2025), and -$182000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 1.13 Mn
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 931,000.00
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -16.82 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 23.10 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 107.70 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -16.74 Mn
10 Longeveron 15.18 Bn 15.16 Bn 264,000.00 293,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 293,000.00
Mar 31, 2026 293,000.00
Dec 31, 2025 1.25 Mn
Dec 31, 2025 1.25 Mn
Sep 30, 2025 -182,000.00
Sep 30, 2025 -182,000.00
Jun 30, 2025 404,000.00
Jun 30, 2025 404,000.00
Mar 31, 2025 -172,000.00
Mar 31, 2025 -172,000.00
Dec 31, 2024 66,000.00
Dec 31, 2024 66,000.00
Sep 30, 2024 66,000.00
Sep 30, 2024 66,000.00
Jun 30, 2024 -116,000.00
Jun 30, 2024 -116,000.00
Mar 31, 2024 249,000.00
Mar 31, 2024 249,000.00
Dec 31, 2023 679,000.00
Dec 31, 2023 679,000.00